It can take years for prostate cancer to turn castration-resistant, when cancer cells stop responding to hormonal therapy.

中科院上海营养与健康研究所秦骏、安徽医科大学梁朝朝、中国科学院分子细胞科学卓越创新中心袁怀瑞、上海交通大学医学院附属仁济医院董樑等人在 Cell 子刊 Cancer Cell 上发表了题为： KMT2C deficiency drives ...

The pre-analytical workflow is one of the primary considerations in the successful use of liquid biopsies for cancer ...

Patients treated with darolutamide who reached ultra-low PSA at any time had lower risk of radiological progression or death versus those with PSA >=0.2 ng/mL, with a risk reduction of 91%, as did ...

Data on the efficacy of radical prostatectomy in managing clinically node-positive prostate cancer have been limited.

双阴性前列腺癌（DNPC）在雄激素剥夺疗法（ADT）后常出现，但其起源和调控机制不明。研究人员开展关于 DNPC 的研究，发现 KMT2C 突变或缺失易引发 DNPC，且 DNPC 源于管腔细胞转分化。这为治疗 DNPC 提供新思路。

The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in ...

该研究旨在对比黑人与白人前列腺癌患者接受 ADT 治疗后的主要不良心血管事件（MACE）和全因死亡率风险。研究人员从 Decision Resources Group（DRG，现 Clarivate）真实世界证据数据库中收集了 1991 - 2020 年接受至少 1 次 ADT 治疗的前列腺癌患者的历史纵向数据。在分析过程中，采用多变量回归模型，对基线转移、BMI（<18.5 vs. ≥18.5 ...

AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the ...

The study investigators identified 24 prospective trials with 2,850 patients. The median patient age ranged between 59 and 77 years. Overall, testosterone recovery, defined at 240 ng/dL, was observed ...

Quoc-Dien Trinh, MD, MBA, discusses a sub-analysis of the phase 3 ARANOTE trial, focusing on Black patients with metastatic ...

AstraZeneca (NASDAQ:AZN) said on Tuesday it will discontinue its late stage trial testing Truqap combination in patients with ...